Steven C. Campbell MD, PhDProfessor of Surgery, Vice Chair, and Program Director, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio
Dr. Campbell is Professor of Surgery, Residency Program Director, Vice Chairman of Urology, and a member of the Center for Urologic Oncology in the Glickman Urological and Kidney Institute at The Cleveland Clinic. He holds the Eric A. Klein Endowed Chair for Urologic Oncology and Education Dr. Campbell obtained BS, MD and PhD degrees at The University of Chicago and then did a Urology Residency at The Cleveland Clinic (1989-1995), followed by a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center (1995-1996). Dr. Campbell’s primary interests include renal cell carcinoma, bladder cancer, tumor angiogenesis, and urology residency training. His background also includes American Foundation for Urological Diseases (AFUD) and Kimmel Research Scholarship Awards, and he is a member of the American Board of Urology Examination Committee. He is currently Chair of the Exam Committee for the Society of Urologic Oncology and Secretary/Treasurer for the Society of Pelvic Surgeons. Dr. Campbell is Co-Editor of Renal Cell Carcinoma (BC Decker, 2009) and Editor of Renal Cell Carcinoma: Clinical Management (Humana Press, 2013) and 100 Questions and Answers about Kidney Cancer (Jones and Bartlett, 2008 and 2012). He was Co-Chair of the AUA Guidelines Panel: Management of the Clinical T1 Renal Mass (J. Urology, 2009). Dr. Campbell has also authored or co-authored “Malignant Renal Tumors” for Campbell/Walsh Urology for the past 4 editions (2000, 2005, 2010, and 20143).
In the past 4 years Dr. Campbell has published primary and review articles on the Management of Small Renal Masses, Techniques of Partial Nephrectomy, Determinants of Renal Function after Partial Nephrectomy, Chronic Kidney Disease (CKD) and its Implications for Urologists, New Perspectives about Acute Kidney Injury, Renal Mass Biopsy, Imaging of Renal Masses, Management of RCC in the Elderly, Benign Renal Masses, Targeted Treatment for Advanced Kidney Cancer, Integration of Surgery and Targeted Treatment for Advanced Kidney Cancer, Staging of Kidney Cancer, and Surveillance of Kidney Cancer Patients after Primary Treatment. In 2014 his efforts are primarily focused on the Implications of CKD due to Surgical Removal of Nephrons and the Relative Importance of Ischemia with Respect to Recovery of Function after Partial Nephrectomy.
As Program Director for the past 7-8 years Dr. Campbell and colleagues have successfully taken their training program through a full cycle of internal and external reviews and have spearheaded multiple initiatives to improve residency training within the Department. A recent initiative has been to develop an electronically administered Case Based Learning Program that recapitulates patient encounters in the clinics, ER and other clinical settings, highlighting fundamental concepts of various disease processes and management, and complimenting the signature textbook in the field, Campbell/Walsh Urology.
Dr. Campbell also oversees the Cleveland Clinic database of over 10,000 kidney cancer patients that supports clinical and translational research efforts, and he collaborates extensively with Dr. Brian Rini of Medical Oncology from a programmatic standpoint with respect to the investigation and management of kidney cancer.
Recent Contributions to PracticeUpdate:
- New Baseline Renal Function After Radical or Partial Nephrectomy
- Distinguishing Benign Renal Tumors With an Oncocytic Gene Expression (ONEX) Classifier
- Benign Renal Oncocytoma vs Chromophobe Renal Cell Carcinoma on Computed Tomography Using Deep Learning
- Early Discharge After Radical Nephrectomy Does Not Increase Complication Risk
- Survival of Patients With Small Renal Masses Undergoing Active Surveillance
- Yearly Chest Imaging for Patients With Small Renal Masses Undergoing Active Surveillance
- The Probability of Aggressive Histology Increases With Increasing Renal Tumor Size
- Blood Transfusions Impact Oncological Outcomes of Surgically Treated Localized Renal Cell Carcinoma
- Cell Cycle Proliferation Score Improves Prediction of 5-Year Mortality After Radical Nephrectomy for Renal Cell Carcinoma
- Survival After Cytoreductive Nephrectomy in Metastatic Non–Clear Cell Renal Cell Carcinoma